DK2822546T3 - Procaspasekombinationsterapi til behandling af cancer - Google Patents

Procaspasekombinationsterapi til behandling af cancer Download PDF

Info

Publication number
DK2822546T3
DK2822546T3 DK13758061.9T DK13758061T DK2822546T3 DK 2822546 T3 DK2822546 T3 DK 2822546T3 DK 13758061 T DK13758061 T DK 13758061T DK 2822546 T3 DK2822546 T3 DK 2822546T3
Authority
DK
Denmark
Prior art keywords
cancer
pac
composition
cells
compound
Prior art date
Application number
DK13758061.9T
Other languages
English (en)
Inventor
Paul J Hergenrother
Rachel C Botham
Timothy M Fan
Mark J Gilbert
Michael K Handley
Avadhut Joshi
Gregory J Riggins
Theodore M Tarasow
Original Assignee
The Board Of Trustees Of The Univ Of Illionis
Vanquish Oncology Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Univ Of Illionis, Vanquish Oncology Inc, Univ Johns Hopkins filed Critical The Board Of Trustees Of The Univ Of Illionis
Application granted granted Critical
Publication of DK2822546T3 publication Critical patent/DK2822546T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Sammensætning, der omfatter: (a) en forbindelse med formlen (I):
(b) forbindelsen PAC-1:
og (c) en farmaceutisk acceptabel diluent, excipiens eller bærer.
2. Sammensætning ifølge krav 1, hvor bæreren omfatter vand og valgfrit en buffer, en cyclodextrin eller en kombination deraf.
3. Sammensætning ifølge krav 2, hvor cyclodextrinen er 2-hydroxypropyl-P-cyclodextrin.
4. Sammensætning ifølge krav 1, hvor koncentrationen af forbindelsen med formlen I er 100 μΜ til 1 mM.
5. Sammensætning ifølge krav 1, hvor koncentrationen af PAC-1 er 2 μΜ til 50 pM.
6. Sammensætning ifølge krav 1, hvor koncentrationen af forbindelsen med formlen I er 250 pM til 750 pM, og koncentrationen af PAC-1 er 5 pM til 30 pM.
7. Sammensætning til anvendelse ved behandling af en cancer hos en patient, hvor sammensætningen er en effektiv mængde af sammensætningen ifølge et hvilket som helst af kravene 1-6, og hvor anvendelsen omfatter, at cancerceller bringes i kontakt med en effektiv mængde af sammensætningen, hvorved cancercellernes vækst eller proliferation inhiberes.
8. In v/Yro-fremgangsmåde til inhibering af cancercellers vækst eller proliferation, hvilken fremgangsmåde omfatter, at cancerceller bringes i kontakt med en effektiv mængde af sammensætningen ifølge et hvilket som helst af kravene 1-6, hvorved cancercellernes vækst eller proliferation inhiberes.
9. Sammensætning til anvendelse ifølge krav 7 eller in wfro-fremgangsmåde ifølge krav 8, hvor cancercellerne er glioblastomceller eller oligodendrogliomceller.
10. Sammensætning til anvendelse ifølge krav 7 eller in w'fro-fremgangsmåde ifølge krav 8, hvor cancercellerne er osteosarkomceller.
11. Sammensætning til anvendelse ifølge krav 7 eller in w'fro-fremgangsmåde ifølge krav 8, hvor det trin, at cancercellerne bringes i kontakt med sammensætningen, inducerer apoptose i cancercellerne.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 7 eller 9-11 eller in v/fro-fremgangsmåde ifølge et hvilket som helst af kravene 8-11, hvor cancercellen samtidig bringes i kontakt med forbindelsen med formlen (I) og PAC-1.
13. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 7 eller 9-11 eller in w'iro-fremgangsmåde ifølge et hvilket som helst af kravene 8-11, hvor cancercellen bringes i kontakt med forbindelsen med formlen (I), inden cancercellen bringes i kontakt med PAC-1.
14. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 7 eller 9-11 eller in v/fro-fremgangsmåde ifølge et hvilket som helst af kravene 8-11, hvor cancercellen bringes i kontakt med PAC-1, inden cancercellen bringes i kontakt med forbindelsen med formlen (I).
15. Sammensætning til anvendelse ifølge krav 7, hvor canceren erglioblastom, oligodendrogliom eller osteosarkom.
DK13758061.9T 2012-03-06 2013-03-06 Procaspasekombinationsterapi til behandling af cancer DK2822546T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607103P 2012-03-06 2012-03-06
PCT/US2013/029391 WO2013134398A1 (en) 2012-03-06 2013-03-06 Procaspase combination therapy for glioblastoma

Publications (1)

Publication Number Publication Date
DK2822546T3 true DK2822546T3 (da) 2017-10-30

Family

ID=49117298

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13758061.9T DK2822546T3 (da) 2012-03-06 2013-03-06 Procaspasekombinationsterapi til behandling af cancer
DK17180400.8T DK3290035T3 (da) 2012-03-06 2013-03-06 Procaspase-kombinationsterapi til behandling af cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17180400.8T DK3290035T3 (da) 2012-03-06 2013-03-06 Procaspase-kombinationsterapi til behandling af cancer

Country Status (14)

Country Link
US (5) US9421202B2 (da)
EP (2) EP3290035B1 (da)
JP (2) JP6222608B2 (da)
KR (1) KR102075811B1 (da)
CN (1) CN104540501B (da)
AU (1) AU2013230985B2 (da)
BR (1) BR112014022123B1 (da)
CA (1) CA2866020C (da)
DK (2) DK2822546T3 (da)
ES (2) ES2646008T3 (da)
IN (1) IN2014MN01944A (da)
MX (1) MX359209B (da)
RU (1) RU2636234C2 (da)
WO (1) WO2013134398A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134474A2 (en) * 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
AU2013230985B2 (en) 2012-03-06 2016-05-12 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
IL256111B2 (en) * 2015-06-05 2023-09-01 Univ Illinois Treatment of pac combinations
KR101712638B1 (ko) 2015-08-19 2017-03-07 한국과학기술연구원 Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제
AU2018368453B2 (en) 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
EP3833342A4 (en) 2018-08-09 2022-07-13 The Board of Trustees of the University of Illinois IMIDAZOTETRAZINE COMPOUNDS
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
CN113473996B (zh) * 2019-03-05 2024-05-24 陶氏环球技术有限责任公司 诱导胱天蛋白酶活性
EP3976062A4 (en) * 2019-05-30 2023-06-14 The Board Of Trustees Of The University Of Illinois PROCASPASE-3 ACTIVATION AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
EP1100932A2 (en) 1998-07-27 2001-05-23 PHARMACIA &amp; UPJOHN COMPANY Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002048329A2 (en) 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2003024955A2 (en) 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
US7632972B2 (en) 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
CN101184491A (zh) * 2005-05-26 2008-05-21 伊利诺伊大学评议会 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2007002254A2 (en) * 2005-06-23 2007-01-04 Merck & Co., Inc. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CA2622867A1 (en) * 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US7886969B2 (en) 2005-12-06 2011-02-15 Visa U.S.A. Inc. Method and system for loading and reloading portable consumer devices
JP2009537636A (ja) 2006-05-19 2009-10-29 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 黒色腫及び他の癌を治療するためのトリフェニルメチルホスホン酸エステルを含めたリン含有化合物
RU2360692C1 (ru) 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, стимулирующее апоптоз клеток лейкемии человека
MX2010007548A (es) 2008-01-11 2010-11-25 Univ California Activadores de procaspasas 3, 6 y 7 efectoras.
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8778945B2 (en) 2009-02-09 2014-07-15 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
TWI386203B (zh) * 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
AU2013230985B2 (en) 2012-03-06 2016-05-12 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma

Also Published As

Publication number Publication date
US10085978B2 (en) 2018-10-02
US20150025083A1 (en) 2015-01-22
US20240082241A1 (en) 2024-03-14
ES2738448T3 (es) 2020-01-22
US11844798B2 (en) 2023-12-19
EP3290035A1 (en) 2018-03-07
JP2018052932A (ja) 2018-04-05
RU2014139955A (ru) 2016-04-27
HK1204985A1 (en) 2015-12-11
US12433885B2 (en) 2025-10-07
EP2822546B1 (en) 2017-07-12
US20190099419A1 (en) 2019-04-04
US9421202B2 (en) 2016-08-23
RU2636234C2 (ru) 2017-11-21
KR20140143771A (ko) 2014-12-17
IN2014MN01944A (da) 2015-07-10
JP2015509964A (ja) 2015-04-02
US10874666B2 (en) 2020-12-29
AU2013230985A1 (en) 2014-10-16
DK3290035T3 (da) 2019-08-05
CA2866020C (en) 2020-09-22
AU2013230985B2 (en) 2016-05-12
US20210290616A1 (en) 2021-09-23
ES2646008T3 (es) 2017-12-11
MX2014010714A (es) 2015-03-10
JP6222608B2 (ja) 2017-11-01
US20170042886A1 (en) 2017-02-16
EP2822546A4 (en) 2015-10-28
CA2866020A1 (en) 2013-09-12
KR102075811B1 (ko) 2020-02-10
BR112014022123A2 (da) 2017-06-20
BR112014022123B1 (pt) 2022-09-20
EP2822546A1 (en) 2015-01-14
CN104540501B (zh) 2016-11-23
EP3290035B1 (en) 2019-05-15
MX359209B (es) 2018-09-19
CN104540501A (zh) 2015-04-22
WO2013134398A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
US12433885B2 (en) Procaspase combination therapy for glioblastoma
AU2016213862B2 (en) Procaspase 3 activation by combination therapy
US11129830B2 (en) PAC-1 combination therapy
US9592229B2 (en) Potent anticancer activity via dual compound activation
HK1204985B (en) Procaspase combination therapy for treating cancer
HK1204971B (en) Potent anticancer activity via dual compound activation